Otter Pharms Drug Patent Portfolio
Otter Pharms owns 2 orange book drugs protected by 22 US patents Given below is the list of Otter Pharms's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11541002 | Oral film compositions and dosage forms having precise active dissolution profiles | 31 Jan, 2040 | Active |
| US8814834 | Injector safety device | 27 May, 2031 | Active |
| US11497753 | Hazardous agent injection system | 19 Mar, 2030 | Active |
| US8480631 | Hazardous agent injection system | 19 Mar, 2030 | Active |
| US8579865 | Hazardous agent injection system | 19 Mar, 2030 | Active |
| US8945063 | Hazardous agent injection system | 19 Mar, 2030 | Active |
| US9421333 | Hazardous agent injection system | 19 Mar, 2030 | Active |
| US10709844 | Injector safety device | 10 Mar, 2029 | Active |
| US11684723 | Injector safety device | 10 Mar, 2029 | Active |
| US9867949 | Injector safety device | 10 Mar, 2029 | Active |
| US8021335 | Prefilled syringe jet injector | 04 Oct, 2026 | Active |
| US11446441 | Prefilled syringe injector | 24 Jan, 2026 | Active |
| US8562564 | Prefilled syringe jet injector | 24 Jan, 2026 | Active |
| US9533102 | Prefilled syringe jet injector | 24 Jan, 2026 | Active |
| US9629959 | Prefilled syringe jet injector | 24 Jan, 2026 | Active |
| US8603514 | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions | 03 Apr, 2024 | Expired |
| US8765167 | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions | 20 Feb, 2024 | Expired |
| US6746429 | Needle assisted jet injector | 12 Apr, 2020 | Expired |
| US7744582 | Needle assisted jet injector | 10 Aug, 2019 | Expired |
| US7776015 | Needle assisted jet injector | 10 Aug, 2019 | Expired |
| USRE44846 | Needle assisted jet injector | 10 Aug, 2019 | Expired |
| USRE44847 | Needle assisted jet injector | 10 Aug, 2019 | Expired |
Latest Legal Activities on Otter Pharms's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Otter Pharms.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 01 Jul, 2024 | US9533102 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 23 Feb, 2024 | US9421333 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 11 Jan, 2024 | US10709844 |
| Patent eGrant Notification | 27 Jun, 2023 | US11684723 |
| Mail Patent eGrant Notification | 27 Jun, 2023 | US11684723 |
| Recordation of Patent eGrant | 27 Jun, 2023 | US11684723 |
|
Email Notification
Critical
| 27 Jun, 2023 | US11684723 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 27 Jun, 2023 | US11684723 |
|
Electronic Review
Critical
| 27 Jun, 2023 | US11684723 |
|
Recordation of Patent Grant Mailed
Critical
| 27 Jun, 2023 | US11684723 |
|
Electronic Review
Critical
| 08 Jun, 2023 | US11684723 |
|
Email Notification
Critical
| 08 Jun, 2023 | US11684723 |
|
Issue Notification Mailed
Critical
| 07 Jun, 2023 | US11684723 |
|
Electronic Review
Critical
| 17 May, 2023 | US11684723 |
|
Application Is Considered Ready for Issue
Critical
| 11 May, 2023 | US11684723 |
Otter Pharms's Drug Patent Litigations
Otter Pharms's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 28, 2014, against patent number US8765167. The petitioner BioDelivery Sciences International, Inc., challenged the validity of this patent, with MonoSol Rx, LLC. as the respondent. Click below to track the latest information on how companies are challenging Otter Pharms's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US8603514 | June, 2017 |
Terminated-Denied
(20 Oct, 2017)
| MonoSol Rx, LLC | Par Pharmaceutical, Inc. |
| US8603514 | June, 2017 |
Terminated-Denied
(20 Oct, 2017)
| MonoSol Rx, LLC | Dr. Reddy’s Laboratories, Inc. |
| US8603514 | November, 2016 |
Terminated-Settled
(06 Oct, 2017)
| MonoSol Rx, LLC et al. | Mylan Technologies, Inc. et al. |
| US8603514 | May, 2016 |
Terminated-Denied
(05 Dec, 2016)
| MonoSol Rx, LLC | Dr. Reddy's Laboratories, Inc. |
| US8603514 | December, 2015 |
Terminated-Denied
(23 May, 2016)
| MONOSOL RX LLC | Teva Pharmaceuticals USA Inc |
| US8765167 | October, 2014 |
FWD Entered
(24 Mar, 2016)
| MonoSol Rx, LLC. | BioDelivery Sciences International, Inc. |
| US8765167 | October, 2014 |
Terminated-Settled
(24 Mar, 2016)
| MonoSol Rx, LLC. et al. | BioDelivery Sciences International, Inc. |
| US8765167 | October, 2014 |
Terminated-Denied
(20 May, 2015)
| MonoSol Rx, LLC. | BioDelivery Sciences International, Inc. |
Otter Pharms Drug Patents' Oppositions Filed in EPO
Otter Pharms drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Sep 11, 2012, by Lts Lohmann Therapie-Systeme Ag. This opposition was filed on patent number EP02801042A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP19150366A | Sep, 2022 | Bandpay & Greuter | Granted and Under Opposition |
| EP06719329A | Oct, 2019 | Bandpay & Greuter | Patent maintained as amended |
| EP09719763A | Jun, 2016 | Ypsomed AG | Revoked |
| EP11157819A | Jun, 2014 | Ahrens, Gabriele | Patent maintained as amended |
| EP02782151A | Jun, 2013 | Acino Pharma AG | Revoked |
| EP02782151A | Jun, 2013 | Germann, Sandra | Revoked |
| EP02801042A | Sep, 2012 | Ahrens, Gabriele | Patent maintained as amended |
| EP02801042A | Sep, 2012 | LTS LOHMANN Therapie-Systeme AG | Patent maintained as amended |
Otter Pharms's Family Patents
Otter Pharms Drug List
Given below is the complete list of Otter Pharms's drugs and the patents protecting them.
1. Otrexup
Otrexup is protected by 19 patents, out of which 5 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8814834 | Injector safety device |
27 May, 2031
(6 years from now)
| Active |
| US11497753 | Hazardous agent injection system |
19 Mar, 2030
(4 years from now)
| Active |
| US8480631 | Hazardous agent injection system |
19 Mar, 2030
(4 years from now)
| Active |
| US8579865 | Hazardous agent injection system |
19 Mar, 2030
(4 years from now)
| Active |
| US8945063 | Hazardous agent injection system |
19 Mar, 2030
(4 years from now)
| Active |
| US9421333 | Hazardous agent injection system |
19 Mar, 2030
(4 years from now)
| Active |
| US10709844 | Injector safety device |
10 Mar, 2029
(3 years from now)
| Active |
| US11684723 | Injector safety device |
10 Mar, 2029
(3 years from now)
| Active |
| US9867949 | Injector safety device |
10 Mar, 2029
(3 years from now)
| Active |
| US8021335 | Prefilled syringe jet injector |
04 Oct, 2026
(1 year, 4 months from now)
| Active |
| US11446441 | Prefilled syringe injector |
24 Jan, 2026
(8 months from now)
| Active |
| US8562564 | Prefilled syringe jet injector |
24 Jan, 2026
(8 months from now)
| Active |
| US9533102 | Prefilled syringe jet injector |
24 Jan, 2026
(8 months from now)
| Active |
| US9629959 | Prefilled syringe jet injector |
24 Jan, 2026
(8 months from now)
| Active |
| US6746429 | Needle assisted jet injector |
12 Apr, 2020
(5 years ago)
| Expired |
| US7744582 | Needle assisted jet injector |
10 Aug, 2019
(5 years ago)
| Expired |
| US7776015 | Needle assisted jet injector |
10 Aug, 2019
(5 years ago)
| Expired |
| USRE44846 | Needle assisted jet injector |
10 Aug, 2019
(5 years ago)
| Expired |
| USRE44847 | Needle assisted jet injector |
10 Aug, 2019
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Otrexup's drug page
2. Sympazan
Sympazan is protected by 3 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11541002 | Oral film compositions and dosage forms having precise active dissolution profiles |
31 Jan, 2040
(14 years from now)
| Active |
| US8603514 | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
03 Apr, 2024
(1 year, 1 month ago)
| Expired |
| US8765167 | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
20 Feb, 2024
(1 year, 2 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Sympazan's drug page